DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C

Information source: Seoul National University Boramae Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Depression

Intervention: Mirtazapine (Drug); Supportive psychotherapy (Other)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Seoul National University Boramae Hospital

Official(s) and/or principal investigator(s):
Won Kim, MD, PhD, Principal Investigator, Affiliation: Seoul Metropolitan Government Boramae Medical Center

Summary

The purpose of this study is to evaluate the anti-depressive efficacy of mirtazapine in depression induced by peginterferon alpha-2a and ribavirin treatment in Korean patients with chronic hepatitis C.

Clinical Details

Official title: Phase 4 Open-labeled Study to Compare the Anti-depressive Efficacy Between Mirtazapine and Psychotherapy for Patients With Interferon-related Depression During Antiviral Therapy for Hepatitis C

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change from baseline in Hamilton Depression Rating Scale (HAMD)-17 at 8 weeks

Secondary outcome:

Change from baseline in quality of life at 8 weeks

Genetic polymorphism

Detailed description: Depression is a common serious adverse event (30%-50%) during the interferon treatment for chronic hepatitis C. Adequate control of depressive symptoms might enable to adhere to antiviral therapy and lead to the favorable prognosis for patients with chronic hepatitis C. Mirtazapine is an effective antidepressant for depressive mood as well as insomnia and anxiety. Mirtazapine has also relatively lower drug-drug interactions, which are important for patients with hepatic dysfunction. In this study, the investigators are going to perform an 8-week, randomized, open label trial comparing anti-depressive efficacy between mirtazapine and supportive psychotherapy in depression induced by peginterferon alpha-2a and ribavirin treatment in Korean patients with chronic hepatitis C.

Eligibility

Minimum age: 20 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Major depressive episode diagnosed with Diagnostic and Statistical Manual Diploma in

Social Medicine-IV (DSM-IV)

- Hamilton Depression Scale (HAMD-17) ≥ 14

Exclusion Criteria:

- Any other axis I primary diagnoses except major depressive disorder

- Having serious adverse events or hypersensitivity to mirtazapine

- Having major depressive disorder prior to the first injection of interferon

Locations and Contacts

SMG-SNU Boramae Medical Center, Seoul 156-707, Korea, Republic of
Additional Information

Starting date: August 2011
Last updated: May 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017